---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-009253"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2026-03-20T23:59:59+00:00"
generated_at: "2026-05-15T09:26:41.897230+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics establishes $750M term loan facility due 2031, repays prior term loans

## Summary
- Borrowed $750M on March 18, 2026 under new term loan; proceeds used to fully repay initial term loans.
- Loan matures March 18, 2031; interest rate is SOFR + margin starting at 4.75% (or base rate + 3.75%).
- Quarterly amortization payments of $37.5M begin Q1 2030; can be deferred if leverage ratio met.
- Also established uncommitted additional facility of up to $250M.
- Loan secured by substantially all assets of borrower and guarantors; includes customary covenants.

## SEC filing metadata
- accession: 0001437749-26-009253
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2026-03-20T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774926009253/0001437749-26-009253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774926009253/tgtx20260319_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-009253
- JSON: https://secwatch.observer/filing/0001437749-26-009253.json
- Plain text: https://secwatch.observer/filing/0001437749-26-009253.txt

## Source-grounded claims
- claim_id: d58f42a987733dbd2ada0b5f5d4052efd166b03f
  claim: TG THERAPEUTICS, INC. incurred term loan of $750 million with Blue Owl Capital Corporation at an applicable margin plus, at the Borrower’s option, either (a) a base rate dete maturing March 18, 2031.
  evidence_excerpt: the Borrower established (i) a $750 million term loan facility (the “2026 Term Loan”), which was borrowed in full on the Closing Date
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000143774926009253/0001437749-26-009253-index.htm
- claim_id: d372afbb073a3de9014456ab2a55cd450878e57d
  claim: TG THERAPEUTICS, INC. amended First Amendment with Blue Owl Capital Corporation, as administrative agent, and the lenders party thereto valued at $750 million term loan facility (effective 2026-03-18).
  evidence_excerpt: On March 18, 2026 (the “Closing Date”), the Company (the “Borrower”) entered into the first amendment agreement, dated as of the Closing Date (the “First Amendment”), by and among the Borrower, certain subsidiaries of the Borrower, as guarantors, the lenders party thereto and Blue Owl Capital Corporation, as administrative agent (the “Administrative Agent”), which amends the financing agreement, dated as of August 2, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000143774926009253/0001437749-26-009253-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.